Boehringer Ingelheim and Zealand Pharma's Survodutide Matches Wegovy in Weight Loss but Trails Zepbound in Phase 3 Trial

on

Boehringer Ingelheim's survodutide, licensed from Zealand Pharma, achieved significant weight loss in a Phase 3 obesity trial, comparable to Wegovy's 12-19% but below Zepbound's 17.8-22.5%14.

Survodutide showed potential to preserve muscle mass, addressing a limitation of both Wegovy and Zepbound1.

Analysts note the weight loss results do not differentiate survodutide from Wegovy but highlight possible advantages in liver health for MASH patients1.

Up to 16.6% weight loss observed after nearly 17 months in the trial4.

Zepbound outperformed Wegovy in head-to-head trials with 20.2% vs. 13.7% weight loss at 72 weeks3.

Sources:

1. https://www.biopharmadive.com/news/survodutide-obesity-drug-results-boehringer-ingelheim-zealand/818664/

3. https://ro.co/weight-loss/zepbound-vs-wegovy/

4. https://www.techtarget.com/pharmalifesciences/news/366642423/Boehringers-dual-agonist-obesity-drug-spurs-up-to-166-weight-loss